Literature DB >> 12243653

New technologies for ablation of small renal tumors: current status.

Joseph L Chin1, Stephen E Pautler.   

Abstract

The diagnostic rate of small, "incidental" tumors which are amenable to local excision or ablation has increased significantly due to widespread use of non-invasive body imaging tests. The role of nephron-sparing tumor-ablative surgery has expanded beyond the traditional circumstances of neoplasms in solitary/functionally solitary kidneys or tumors present bilaterally. Due to technologic advances, possible therapeutic options now include open surgery, laparoscopic, percutaneous and extraciorporeal approaches, in addition to surveillance in some cases. This review will concentrate on the new energy sources available for tumor ablation rather than the different surgical approaches, with a detailed review of renal cryoablation, radiofrequency and high intensity focused ultrasound. The emphasis is on the experimental data and the limited clinical data available to date, and challenges and current limitations of the various modalities.

Entities:  

Mesh:

Year:  2002        PMID: 12243653

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  3 in total

1.  Thermal protection during percutaneous thermal ablation of renal cell carcinoma.

Authors:  Anthony W Kam; Peter J Littrup; McClellan M Walther; Julia Hvizda; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2004-07       Impact factor: 3.464

2.  Dynamic frame selection for in vivo ultrasound temperature estimation during radiofrequency ablation.

Authors:  Matthew J Daniels; Tomy Varghese
Journal:  Phys Med Biol       Date:  2010-07-30       Impact factor: 3.609

3.  Percutaneous US-guided RF thermal ablation for malignant renal tumors: preliminary results in 13 patients.

Authors:  Andrea Veltri; Giuseppina De Fazio; Valeria Malfitana; Giuseppe Isolato; Dario Fontana; Alessandro Tizzani; Giovanni Gandini
Journal:  Eur Radiol       Date:  2004-07-27       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.